Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
These multisystem benefits create a healthcare ROI calculation where GLP-1 therapy prevents conditions with substantially higher lifetime treatment costs than the drug itself
The difference in weight loss is significant
Under normal circumstances, fatty foods trigger the release of cholecystokinin (CCK) and other hormones that slow gastric emptying to allow adequate time for fat digestion and absorption in the small intestine
Lilly's first Phase 3 readout (TRIUMPH4) reported strong results in people with obesity/overweight and knee osteoarthritis, including: ~28.7% average weight loss at 68 weeks at the 12 mg dose (topline reporting), plus improvements in pain and function measures The important phrase there is "topline"
Wegovy (semaglutide 2.4 mg) is typically recommended for up to 2 years of treatment
